Detail
Článek
FT
Medvik - BMČ
  • Je něco špatně v tomto záznamu ?

Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma

E. Křepela, P. Daňková, E. Moravčíková, A. Křepelová, J. Procházka, J. Čermák, J. Schützner, P. Zatloukal, K. Benková

Jazyk angličtina Země Řecko

Typ dokumentu práce podpořená grantem

Perzistentní odkaz   https://www.medvik.cz/link/bmc12008639
E-zdroje

NLK Free Medical Journals od 2006 do Před 1 rokem

Members of the inhibitor of apoptosis protein (IAP) family, survivin and X-chromosome-linked IAP (XIAP), contribute to apoptosis resistance of cancer cells, and an increase in their expression may elevate the apoptotic threshold of malignant tumours during their growth and progression. In the present study, we investigated the expression status of survivin and its interactants hepatitis B X-interacting protein (HBXIP) and XIAP in non-small cell lung carcinoma (NSCLC) cell lines and NSCLC tumours and matched lungs from surgically treated patients in relation to their clinicopathological data. The expression of survivin, HBXIP and XIAP mRNAs was quantitated by real-time RT-PCR. The expression of survivin and XIAP proteins was analysed by Western blotting and ELISA. Survivin mRNA and protein levels were highly upregulated in NSCLC cells and tissues as compared to the lungs. In fact, the levels of survivin mRNA and protein in the tumours were more than 10-fold higher in 96 (64%) and 72 (82%) of the 150 and 88 examined NSCLC patients, respectively. The expression of survivin mRNA was higher in squamous cell lung carcinomas than in lung adenocarcinomas (LACs; P=0.003) and in less-differentiated tumours than in well-differentiated ones (P=0.007). The level of survivin protein was higher in stage IB and stage II+III tumours (P=0.049 and P=0.044), than in stage IA tumours. The BIRC5 promoter polymorphism at nucleotide -31 did not influence the expression of survivin mRNA and protein in NSCLC cells and tumours. HBXIP mRNA was abundantly expressed in NSCLC cell lines and NSCLC tumours and lungs, while its level was comparable in the tumours and lungs. The expression of XIAP mRNA in NSCLC cell lines and NSCLC tumours and lungs was not significantly different. However, the expression of XIAP protein was higher in NSCLC tumours, particularly in LACs, as compared to the lungs (P=0.017 and P=0.004). In conclusion, the overexpression of survivin in the majority of NSCLCs together with the abundant or upregulated expression of HBXIP and XIAP suggest that tumours are endowed with resistance against a variety of apoptosis-inducing conditions.

000      
04119naa a2200517 a 4500
001      
bmc12008639
003      
CZ-PrNML
005      
20121203114101.0
008      
120316s2009 gr eng||
009      
AR
040    __
$a ABA008 $b cze $d ABA008
041    0_
$a eng
044    __
$a gr
100    1_
$a Křepela, Evžen $7 xx0083612 $u Laboratories of Molecular and Cell Biology, University Hospital Bulovka, Prague, Czech Republic. krepelae@fnb.cz
245    10
$a Increased expression of inhibitor of apoptosis proteins, survivin and XIAP, in non-small cell lung carcinoma $c E. Křepela, P. Daňková, E. Moravčíková, A. Křepelová, J. Procházka, J. Čermák, J. Schützner, P. Zatloukal, K. Benková
520    9_
$a Members of the inhibitor of apoptosis protein (IAP) family, survivin and X-chromosome-linked IAP (XIAP), contribute to apoptosis resistance of cancer cells, and an increase in their expression may elevate the apoptotic threshold of malignant tumours during their growth and progression. In the present study, we investigated the expression status of survivin and its interactants hepatitis B X-interacting protein (HBXIP) and XIAP in non-small cell lung carcinoma (NSCLC) cell lines and NSCLC tumours and matched lungs from surgically treated patients in relation to their clinicopathological data. The expression of survivin, HBXIP and XIAP mRNAs was quantitated by real-time RT-PCR. The expression of survivin and XIAP proteins was analysed by Western blotting and ELISA. Survivin mRNA and protein levels were highly upregulated in NSCLC cells and tissues as compared to the lungs. In fact, the levels of survivin mRNA and protein in the tumours were more than 10-fold higher in 96 (64%) and 72 (82%) of the 150 and 88 examined NSCLC patients, respectively. The expression of survivin mRNA was higher in squamous cell lung carcinomas than in lung adenocarcinomas (LACs; P=0.003) and in less-differentiated tumours than in well-differentiated ones (P=0.007). The level of survivin protein was higher in stage IB and stage II+III tumours (P=0.049 and P=0.044), than in stage IA tumours. The BIRC5 promoter polymorphism at nucleotide -31 did not influence the expression of survivin mRNA and protein in NSCLC cells and tumours. HBXIP mRNA was abundantly expressed in NSCLC cell lines and NSCLC tumours and lungs, while its level was comparable in the tumours and lungs. The expression of XIAP mRNA in NSCLC cell lines and NSCLC tumours and lungs was not significantly different. However, the expression of XIAP protein was higher in NSCLC tumours, particularly in LACs, as compared to the lungs (P=0.017 and P=0.004). In conclusion, the overexpression of survivin in the majority of NSCLCs together with the abundant or upregulated expression of HBXIP and XIAP suggest that tumours are endowed with resistance against a variety of apoptosis-inducing conditions.
590    __
$a bohemika - dle Pubmed
650    02
$a adaptorové proteiny signální transdukční $x biosyntéza $7 D048868
650    02
$a dospělí $7 D000328
650    02
$a senioři $7 D000368
650    02
$a western blotting $7 D015153
650    02
$a nemalobuněčný karcinom plic $x metabolismus $7 D002289
650    02
$a ELISA $7 D004797
650    02
$a ženské pohlaví $7 D005260
650    02
$a exprese genu $7 D015870
650    02
$a stanovení celkové genové exprese $7 D020869
650    02
$a lidé $7 D006801
650    02
$a inhibitory apoptózy $7 D051034
650    02
$a nádory plic $x metabolismus $7 D008175
650    02
$a mužské pohlaví $7 D008297
650    02
$a proteiny asociované s mikrotubuly $x biosyntéza $7 D008869
650    02
$a lidé středního věku $7 D008875
650    02
$a messenger RNA $x analýza $7 D012333
650    02
$a polymerázová řetězová reakce s reverzní transkripcí $7 D020133
650    02
$a X-vázaný inhibitor apoptózy $x biosyntéza $7 D051636
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Daňková, Petra
700    1_
$a Moravčíková, Erika
700    1_
$a Křepelová, Anna, $d 1955- $7 ja20020046544
700    1_
$a Procházka, Jan
700    1_
$a Čermák, Jan
700    1_
$a Schützner, Jan, $d 1953- $7 mzk2005294945
700    1_
$a Zatloukal, Petr, $d 1955-2012 $7 jn20000402715
700    1_
$a Benková, Kamila, $d 1963- $7 xx0077689
773    0_
$t International Journal of Oncology $p Int J Oncol $g Roč. 35, č. 6 (2009), s. 1449-1462 $w MED00002350 $x 0946-1965
773    0_
$p Int J Oncol $g 35(6):1449-62, 2009 Dec
910    __
$a ABA008 $b x $y 4
990    __
$a 20120319124600 $b ABA008
991    __
$a 20121203114132 $b ABA008
999    __
$a ok $b bmc $g 901984 $s 765534
BAS    __
$a 3
BMC    __
$a 2009 $b 35 $c 6 $d 1449-1462 $m International journal of oncology $x MED00002350
LZP    __
$a 2012-1Q10/